Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : The proceeds will advance company's lead drug, a potential first-in-class, disease-modifying recombinant protein designed to modulate the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells ,into clinical development i...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $30.0 million
Deal Type : Series A Financing